Sertindole in the long-term treatment of schizophrenia

International Clinical Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 231-237

  Hale, Anthony S ^a   Azorin, Jean M ^b   Lemming, Ole M ^c   Mæhlum, Eli ^c  

^a KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c H LUNDBECK A S   (Denmark)

Author keywords

antipsychotic; atypical; extrapyramidal symptoms; safety; sertindole; tolerability

Indexed keywords

ALKALINE PHOSPHATASE; HALOPERIDOL; PROLACTIN; SERTINDOLE;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; OPEN STUDY; ORTHOSTATIC HYPOTENSION; POSITIONAL DIZZINESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TREMOR; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84862119972     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328354dcda     Document Type: Article

References (40)

1. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
2. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101. (Pubitemid 28026679)
3. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C (2006). Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 15:873-879. (Pubitemid 44941640)
4. Azorin JM, Strub N, Loft H (2006). A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 21:49-56. (Pubitemid 43175123)
5. Chung A, Chua S (2010). Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 25:646-666.
6. Daniel DG, Wozniak P, Mack RJ, McCarthy BG (1998). Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 34:61-69. (Pubitemid 28176303)
7. De Hert M, Mittoux A, He Y, Peusken J (2010). A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res 23 (2-3):276-277.
8. De Hert M, Mittoux A, He Y, Peuskens J (2011). Metabolic parameters in the short-and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 261:231-239.
9. De Oliveira I, Juruena MF (2006). Treatment of psychosis: 30 years of progress. J Clin Pharm Ther 31:523-534. (Pubitemid 44813765)
10. Eckardt L, Breithardt G, Haverkamp W (2002). Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300:64-71. (Pubitemid 34028509)
11. Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH (1997). Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 171:265-268. (Pubitemid 27400303)
12. Freedman R (2003). Schizophrenia. N Engl J Med 349:1738-1749. (Pubitemid 37315012)
13. Gallhofer B, Jaanson P, Mittoux A, Tanghøj P, Lis S, Krieger S (2007). Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40:275-286. (Pubitemid 350232820)
14. Gorwood P (2006). Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 16 (Suppl 3):S156-S162. (Pubitemid 44175820)
15. Hale A, Azorin JM, Kasper S, Maier W, Syvä lahti E, van der Burght M, et al. (2000a). Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a phase III trial. Int J Psych Clin Pract 4:47-54. (Pubitemid 30198336)
16. Hale A, Azorin JM, Kasper S, Maier W, Syvä lahti E, van der Burght M, et al. (2000b). Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psych Clin Pract 4:55-62. (Pubitemid 30198337)
17. Hamner M (2002). The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 14:163-173. (Pubitemid 36172565)
18. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T (2006). Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 13:1311-1316. (Pubitemid 44453698)
19. Hondeghem LM, Carlsson L, Duker G (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103:2004-2013. (Pubitemid 32322230)
20. Hyttel J, Nielsen JB, Nowak G (1992). The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 89:61-69.
21. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010). Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT(2A) receptor mechanisms. Psychopharmacology 208:23-36.
22. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006). Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122-127. (Pubitemid 43171066)
23. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, et al. (2007). Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 68:75-80. (Pubitemid 46220127)
24. Kasper S, Hale A, Azorin JM, Mü ller HJ (1999). Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249:S1-S14.
25. Kasper S, Moller H-J, Hale A (2010). The European Post-marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psy Clin Neur 260:59-68.
26. Mohr P (2007). Quality of life in the long-term treatment and the role of secondgeneration antipsychotics. Neuroendocrinol Lett Suppl 1:117-133. (Pubitemid 46534377)
27. Moore N (2002). Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psych Clin Pract 6 (Suppl 1): S3-S9. (Pubitemid 36125660)
28. Neckelmann D, Mæhlum E,Waage IM (2010). Sertindole and fluoxetine overdose with benign outcome. Nord J Psychiatry 64:288.
29. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93. (Pubitemid 40677047)
30. Nielsen J, Graff C, Hardahl T, Andersen MP, Kristoffersen J, Struijk JJ, et al. (2009). Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 19:702-707.
31. O'Keane V, Meaney AM (2005). Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26-31. (Pubitemid 40129379)
32. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008). Reversal of subchronic PCPinduced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657-2666.
33. Sánchez C, Arnt J, Dragsted N, Hyttel J, Love Lemboel H, Meier E, et al. (1991). Neurochemical and in vivo pharmacological profile of sertindole, a limbicselective neuroleptic compound. Drug Dev Res 22:3239-3250.
34. Scheen A, van Winkel R, De Hert M (2008). Neuroleptic treatment and metabolic disorders. Med Mal Metabol 2:593-599.
35. Skarsfeldt T (1992). Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33.
36. Smith M, Hokins D, Peveler R, Holt R, Woodward M, Ismail K (2008). First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406-411. (Pubitemid 351809892)
37. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997). Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (Suppl 1):S29-S35. (Pubitemid 27171186)
38. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 122:345-355.
39. Trenton A, Currier G, Zwemer F (2003). Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 17:307-324. (Pubitemid 36469970)
40. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782-791. (Pubitemid 27230100)